PMID- 28189389
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20220316
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 98
DP  - 2017 Oct
TI  - The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor 
      microenvironments.
PG  - 71-78
LID - S1043-4666(17)30036-4 [pii]
LID - 10.1016/j.cyto.2017.02.001 [doi]
AB  - Infiltration of leukocytes is one of the hallmarks of the inflammatory response. 
      Among the leukocyte populations, neutrophils are the first to infiltrate, 
      followed by monocytes and lymphocytes, suggesting the presence of mediators that 
      specifically recruit these cell types. Cytokine-like chemoattractants with 
      monocyte chemotactic activity, such as lymphocyte-derived chemotactic factor 
      (LDCF) or tumor-derived chemotactic factor (TDCF), were reported as molecules 
      that could play a critical role in the recruitment of monocytes into sites of 
      immune responses or tumors; however, their identities remained unclear. In the 
      1980s, researchers began to test the hypothesis that leukocyte chemotactic 
      activity is a part of the wider activities exhibited by cytokines, such as 
      interleukin-1 (IL-1). In 1987, we demonstrated, for the first time, the presence 
      of a cytokine like chemoattractant with cell type-specificity (now known as the 
      chemokine interleukin-8 or CXC chemokine ligand 8) that was different from IL-1. 
      This led us to the purification of the second such molecule with monocyte 
      chemotactic activity. This monocyte chemoattractant was found identical to the 
      previously described LDCF or TDCF, and termed monocyte chemoattractant protein-1 
      (MCP-1). Isolation of MCP-1 created a revolution in not only inflammation but 
      also cancer research that continues today, and MCP-1 has become a molecular 
      target to treat patients with many diseases. In this review, I will first 
      describe a history associated with the discovery of MCP-1 and then discuss 
      complex mechanisms regulating MCP-1 production in tumor microenvironments.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Yoshimura, Teizo
AU  - Yoshimura T
AD  - Department of Pathology and Experimental Medicine, Graduate School of Medicine, 
      Dentistry and Pharmaceutical Sciences, Okayama University, Japan. Electronic 
      address: yoshimut@okayama-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170208
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (CCL2 protein, human)
RN  - 0 (CXCL8 protein, human)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines)
RN  - 0 (Chemotactic Factors)
RN  - 0 (Interleukin-8)
SB  - IM
MH  - Chemokine CCL2/*immunology/isolation & purification
MH  - Chemokines/immunology
MH  - Chemotactic Factors/*immunology
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - Humans
MH  - Inflammation/*immunology/physiopathology
MH  - Interleukin-8/immunology
MH  - Leukocytes/immunology
MH  - Monocytes/immunology
MH  - Neutrophils/immunology
MH  - Tumor Microenvironment/*immunology
OTO - NOTNLM
OT  - CCL2
OT  - Chemokine
OT  - MCP-1
OT  - Tumor microenvironment
EDAT- 2017/02/13 06:00
MHDA- 2018/04/25 06:00
CRDT- 2017/02/13 06:00
PHST- 2016/12/06 00:00 [received]
PHST- 2017/02/01 00:00 [accepted]
PHST- 2017/02/13 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2017/02/13 06:00 [entrez]
AID - S1043-4666(17)30036-4 [pii]
AID - 10.1016/j.cyto.2017.02.001 [doi]
PST - ppublish
SO  - Cytokine. 2017 Oct;98:71-78. doi: 10.1016/j.cyto.2017.02.001. Epub 2017 Feb 8.